NGM NGM Biopharmaceuticals Inc

NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an overview of the company and provide a business update at three upcoming investor conferences.

Wednesday, November 18, 2020Event: Jefferies Virtual London Healthcare ConferenceTime: 12:00 pm ET

Wednesday, November 18, 2020Event: Stifel 2020 Virtual Healthcare ConferenceTime: 2:40 pm ET

Monday, November 23, 2020Event: 32nd Annual Piper Sandler Virtual Healthcare ConferenceTime: 12:00 pm ET

A live webcast of these presentations will be available under the Investors and Media section of NGM’s website at https://ir.ngmbio.com/events-presentations. A replay of the presentation will be archived on NGM’s site for 90 days following the event.

About NGM Biopharmaceuticals, Inc.

NGM is a biopharmaceutical company focused on discovering and developing novel therapeutics based on scientific understanding of key biological pathways underlying liver and metabolic diseases, retinal diseases and cancer. We leverage our biology-centric drug discovery approach to uncover novel mechanisms of action and generate proprietary insights that enable us to move rapidly into proof-of-concept studies and deliver potential first-in-class medicines to patients. At NGM, we aspire to operate one of the most productive research and development engines in the biopharmaceutical industry, with multiple programs in clinical development. Visit us at www.ngmbio.com for more information.

Investor Contact:Alex Schwartzir@ngmbio.com

Media Contact:Liz Melonemedia@ngmbio.com